Approach

Defining the requirement

Every engagement begins with a working session, in person, by video, or over a written scoping document, to establish exactly what the buyer needs and why. We ask about the clinical or operational context the product will sit in, the volumes involved, the regulatory jurisdiction the product needs to clear, any incumbent product it needs to be compared against, and the constraints that actually govern the decision: budget range, timeline, service and support expectations, and whether the buyer has a list of candidate manufacturers already or needs one built.

This stage matters more than it looks. An evaluation criterion that seems generic in the abstract, such as "reliable supply," means something different to a single-site clinic ordering modest volumes than to a national tender requiring guaranteed delivery of tens of thousands of units on a fixed schedule. We write the scope down and confirm it with the client before any evaluation work begins, so the criteria used later in the comparison are the client's actual priorities, not our assumptions about them.

Mapping the field

With the requirement defined, we build or refine the list of candidate manufacturers. Where the client already has a shortlist in mind, we start there and add any credible candidates the client may not be aware of. Where the client is starting from a blank field, we build the candidate list from manufacturer registries, trade and export data, exhibitor lists from relevant trade shows, and direct manufacturer outreach. The goal at this stage is coverage, not judgment: we want to know who is actually making and exporting a credible version of the product in question before we start deciding which of them is best.

Testing the evidence

This is the core of the engagement and, by a wide margin, the stage that takes the most time. For each candidate that survives the initial screen, we request the underlying technical file: validation and verification data, clinical or analytical study reports, quality management system documentation, classification and regulatory clearance records, and service and warranty terms. Where a manufacturer's public documentation is thin, we go back to them directly with specific questions, and we note in the final report where a manufacturer was unable or unwilling to substantiate a claim.

We read study designs closely rather than taking headline figures at face value. A diagnostic manufacturer's claimed specificity is only meaningful alongside the reference method it was measured against, the sample size, and the population the study was run in; equipment uptime and service-life claims are only meaningful alongside the duty cycle and environment they were tested under. Where reference calls with existing users of a product are useful and feasible, we arrange them and fold what we learn into the evaluation, clearly separated from the manufacturer's own claims.

Comparing systematically

Once the evidence is assembled for every candidate, we compare it against the criteria agreed at the scoping stage, using the same evaluation axes described on the services page: performance, manufacturing and quality maturity, regulatory standing, serviceability and total cost of ownership, and supply reliability, weighted according to what matters most for this particular buyer. We write the comparison in prose, supported by the underlying documents, rather than reducing it to a numeric score that obscures the reasoning behind it. A buyer should be able to see why one product ranks ahead of another, not just that it does.

The shortlist report

The deliverable is a written report identifying two to four recommended candidates (fewer if the field is genuinely thin, more if the client's use case warrants keeping options open), with the evidence and reasoning behind each recommendation, and an honest account of any candidate that looked promising on paper but did not hold up once its documentation was reviewed. The report is written to be handed directly to a procurement committee, a clinical or scientific review board, or a tender evaluation panel, with source documents referenced so a reviewer can trace any claim back to where it came from.

After the report

Our role typically concludes when the shortlist report is delivered and any follow-up questions from the client's internal stakeholders are answered. What happens next, negotiating terms, arranging import and logistics, and placing the order, is the buyer's process, and we are not positioned in the middle of that transaction. Clients who want the category watched over time, rather than evaluated once, can scope a monitoring arrangement instead; that is described on the services page.

What we need from you

The quality of an evaluation depends heavily on what the client can tell us at the outset. Useful inputs include any existing candidate list, prior purchase history and known pain points with an incumbent product, the specific regulatory jurisdiction the product will be imported into, sample volumes or throughput requirements, and access to a technical or clinical stakeholder who can answer questions as they come up during the evidence review. None of this needs to be polished before you send it; a rough internal document or even a conversation is enough for us to build a proper scope from.